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l Summary
Elevated levels of procoagulant proteins factor II, factor VIII, factor
IX, factor XI and fibrinogen are associated with an increased risk of
venous thrombosis. In a pdpulation-based case-control study on venous
thrombosis (Leiden Thrombophilia Study, LETS) we investigated
whether elcvatcd coagulation factor X (FX) levels are, a risk factor for
venous thrombosis and whether FX levels are determin&i by polymor-
phisms in the promoler region of the FX-gene. We found that subjects
with high F;X levels (above the 90th percentüe, > 126 U/dl) had a
1.6-fold increased risk ,of venous thrombosis. The highest risk
(OR = 4,-3.95% confidence intcrval: 1.5-12) was found in the subgroup
of prerhenopausal women who are not using oral contraceptives.
However, these estimated risks disappeared after adjustment for other
vitamin K-dependent coagulation factors II, VII and IX. To study the
influence of genotypic Variation on plasma FX levels we assessed four
polymorphisms in the promoter region of the FX gene: a TTGTGA
insertion between position -343A and -342G, a C/T polymorphism at
Position -222, a C/A polymorphism at position -220 and a C/T poly-
morphism at position -40. No relationship between these investigated
genotypes and FX levels was observed. We conclude that high FX
levels predict risk of thrombosis, but are not a risk factor for venous
thrombosis when the levels of other vitamin K-dependent proteins are
taken into account.
Introduction
During the past years the search for causes of deep-vein thrombosis
has led to the identification of a number of new risk factors, which can
be genetic or acquired (for a review see ref. 1). The development of a
deep-vein thrombosis may in theory be the result of local disturbances
in the hemostatic balance due to enhanced procoagulant, reduced anti-
coagulänt or reduced fibrinolytic activity. Reduced anticoagulant
activity resulting from deficiencies of antithrombin (2), protein C (3)
and protein S (4) and resistance to activated protein C (5) [in the
presence (6-8) or absence of factor V Leiden (9)] increases the risk of
venous thrombosis. Elevated levels of procoagulant factors Π (10), VIII
(l 1), IX (12), XI (13) and fibrinogen (14) have also been shown to lead
to an increased thrombosis risk.
Factor X (FX), the zymogen of a vitamin K-dependent serine
protease, plays a central role in the coagulation cascade (for a review
see ref. 15).-It can be activated either by the intrinsic contact-activated
pathway or by the extrinsic tissue factor pathway. Activated FX (FXa)
in association with its cofactor activated factor V (FVa) catalyzes the
conversion of prothrombin into thrombin in the presence of phospho-
lipids and calcium ions (16-18). Thrombin in turn converts fibrinogen
into insoluble fibrin. FXa is inhibited by antithrombin with which it
forms a stable inactive complex. Furthermore, prothrombinase activity
is regulated by activated protein C, which inactivates FVa and FVIIIa.
The main inhibitor of the extrinsic pathway is the factor Xa-dependent
tissue factor pathway inhibitor (TFPI). FX deficiency results in a
serious bleeding disorder which points to an essential role for FX in
hemostasis (15).
The gene for FX is located on chromosome 13q34-qter in close
proximity to the gene for FVII and Spans approximately 25 kilobases,
containing 8 exons (19). The overall domain structure of FX is highly
homologous to that of the other vitamin K-dependent coagulation
factors. Expression of the FX gene occurs primarily in the liver (20,
21).
In this study we investigated whether elevated FX levels are asso-
ciated with thrombosis risk. Furthermore, we examined four polymor-
phisms in the promoter region of the FX gene and their relation with FX
levels, äs there have been a number of reports which showed genetical-
ly determined differences in plasma levels for some components of the
blood coagulation System [i.e. factor VII (22), fibrinogen (23), protein
C (24), factor II (10), PAI-1 (25)]. This study was part of a large popu-
lation based case-control study on venous thrombosis, the Leiden
Thrombophilia Study (LETS).
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Patients and Methods
Subjects
The design of our population-based case-control study (Leiden Thrombo-
philia Study, LETS) has been described previously (26). Patients with a first
episode of deep-vein thrombosis were selected from the files of three antico-
agulation clmics in the Netherlands. All patients were younger than 70 years and
were not known to have a malignant disorder. Acquaintances and partners of
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the patients served äs controls. The study included 474 patients and 474 age-
and sex-matched healthy controls. The ratio of men to women was 1:1.3 and
mean age was 47 years for both patients (ränge, 16 to 70 years) and controls
(ränge, 16 to 73 years). Venepuncture took place at least six months after the
thrombotic event.
Forty-eight of the patients and one of the control subjects were on long term
oral anticoagulant therapy at the time of the venepuncture. For analyses
concerning FX levels, these 49 subjects were excluded.
To investigate the relationship between FX levels and oral contraceptive
use, an additional selection was raade, äs described before (27, 28). Preme-
nopausal women aged 15-49 were selected. Women who were pregnant, within
30 days post-partum, with a recent miscarriage or who had used only depot
contraceptives at the index date, were excluded.
Blood Collection
Venous blood was collected into tubes containing 0.106 mol/L trisodium
citrate. Plasma was prepared by centrifugation for 10 min at 2000 g at room
temperature and stored at -70° C. High molecular weight DNA was isolated
from leukocytes by Standard methods and stored at 4° C.
Factor X Antigen Measurements
Factor X antigen (FXag) levels were measured by enzyme linked immuno-
sorbent assay (ELISA). Plastic 96-well microtiter plates were coated with
rabbit anti-human FX polyclonal antibodies (DAKO A/S, Glostrup, Denmark;
4 μg/ml, 100 μΐ/well) during an overnight incubation at 4° C. One hundred
microliter of diluted plasma sample (dilution buffer: 50 mM TEA pH 7.5,
100 mM NaCl, 10 mM EDTA, 0.1% Tween-20) was added to the wells and
plates were incubated at room temperature for 2 h. Subsequently, 100 μΐ of a
1:1500 dilution of peroxidase-conjugated rabbit anti-human FX (DAKO A/S,
Glostrup, Denmark) was added to the wells. After 2 h incubation at room tem-
perature, the plate was incubated with Substrate buffer (0.1 M sodium acetatt
pH 5.5, 0.1 mg/ml tetramethyl-benzidine, H202, 100 μΐ/well). After 10 min
the color reaction was stopped by adding 2 M H2S04 (100 μΐ/well) and read
spectrophotometrically at 450 nm. Between all incubation Steps, the wells were
washed 5 times with dilution buffer. A calibration curve was obtained using
1:200 to 1:12800 dilutions of pooled normal plasma. FXag level of a plasma
sample was calculated äs the mean result of the measurements of three different
independent dilutions (1:800, 1:1600,1:3200). FXag levels were expressed in
units per deciliter (U/dl). By definition l ml pooled normal plasma contains
l unit. Results were accepted when the coefficient of Variation (CV) was less
man 10%, otherwise the measurement was repeated. Under these conditions the
interassay CV was 3.2% (n = 42) at a FXag level of about 100 U/dl and 7.0%
(n = 42) at a livcl of aboul -10 Γ/dl. Al a ΓΧ:ιι: k:\el of aboui !(K) U/dl ihe
intra-assay C'\ »äs 2.7',·' ·ιι - 261. 'Iln: I 'LISA is spccii'ic for FX und no
crossreacüviiy u i i h o i h o r ^ i i a n n n K-dopendem proiciriswasdcii'clcdtFXdd).
cientplasmaL'ives MO.-L'nah.
Measuremciiis öl lacior VII. lacior II and lacior IX levvl.s have beende.
scribedbefore ( 1 0 . 1 2 . 1 - Ι Ί . Iw'ioi I I ac i iv i iy «äs incasurcd wiihachromogenic ."·.
method using S-2238 ((.'hruinogcnit. Mölndal. Swcden) and Kchis carintüK' ·'°**
snake venom iSigma Chemical Co. Si. Louis, MO ι on an ACL-200 (IQt...;.'"!
Factor VII was nieasuicd usiiii; Thromhorel S reagenl ('Bchringwcrke'AG,' · '·ί<ϊ
Warburg, Gennaiui and Ι·\ΊΙ delicicni plasma (Organon Teknica, Durham, •'•'•.ia
USA) (14). Facior IX was mcasured b> an I-I.1SA using commcrcial rabbit an- '· Ϊ-Ϊ3
tifactor IX aniibodics äs capmre ainibodies (DAKO A/S, Gloslrup, DenraaAt'.: ··'·$$
Bound FIX wa.s dcicvicd wiih non (.'a"-de[)endenl anüfaclor IX JgG βϊ"'"*""
conjugated to hoisirradish pcroxidasc ί 12). ..·,·
'·ΐΐ·$?
Genetic Analysn
To perform a gcnciic analy«is of lour polymorphisms in the promdier:'· ·
region of the facmr X t'enc: a ΊΊ'(.ΊΤ(ϊΛ inserlion hciwccn position -343A and ·''
-342G [numberinü according 10 Miao et al (3())|. a C.'/T polymorphism'n:·;'·
position -222. a (VA polyrnorphism al posiiion -220 and a CVTrwIymoipWiini·;''
at position -40 (311. wc doigncd -l seis of oligonucleoiidc primers, derived '
from the genomic scijucnce (Table l i (30.32). l.'sing diese primers, DNA frag- · ;.
ments were amplified h\ polymerase chain reaclion (PCKj. Amplificationwid). ··'
primers 96-348 and 96-349 resulied in a 269 bp (Vaginen!, when the TTGTGÄ".'-':
insertion is absein and in a 275 bp Iragmeiii. when Ihis inscrtion is preseeL ': .
These fragmeiu·- could bc disiinguished on gcl. In heiero/.ygoies an additiooat;:'.
heteroduplex band was obscrved. Amplilicaiion wiih primers 96-824 and :·:
96-360 introdiiccd an ,1/κ·ΝΙ sile i-CAGNNN/nXi-) in Ihe amplified DNA'·;,;
fragment when a T is prcscni al position -222. The resulling 149 bp J
fragment was cul by Λ/wNI inio l'ragmenls of 120 and 29 bp.,
with primers 96-364 and 96-823 introdiiccd a CVitSl site (-C
amplified DNA fragmeni when a C is prcscni at posilion -220. Γη ihisnu
the 148 bp PCR fragmcm was cul by CaM inlo fragmenls of 120 and j
With primers hXupslr and 96-355 a 2 1 1 bp fragmeni was amplified. Di
with Alul resulied in l'ra»meni.s of 136 and 75 hpinca.seofa-40Callelea
fragments of 110. 75 anil 26 bp in case of a -40 T allclc.
's
StatisticalAnalyiis
Odds ratios (ORj were calculated in ihe Standard unmatchcd ,fi
Ninety-five perccni conlklencc imervals (95'ί· CD were conslructcd
to Woolf (33). \V'e adjnsled for ihe malchin» variables agc and scx äs
putative confoundcrs (oral coniracepiive use. \ i iamin K-dc|x;ndent clottig)| ^'?















































The underlined nucleotides in the mutagenic primer sequences deviate from the normal scqucncc
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s Fll, FVII and HX) h\ uncondiiionul lowiii· iciircssion. ΡΠ, FVII and
Ucvels werecntered imo ihc loaislic modcl äs catcuon/cd variables (dicho-
l at Ihi! Will pcrccnlilc). F.nlcring «l Fll. 1;V II and FIX levels into the
: modil äs conlimious variables »a\c siniilar resiilts Fhe OR is used äs a
·. of thc relative nsk, which mdicatc» ihc risk öl' developing venous
"ifirombosis in a caicgory ofcxpuiurc relative u> ihc icl'eicnce category. An OR
f l indicates no cl'fccl im ri.sk. while an OR abiuo I indicnies an increase in risk.
^Variables Affecting l'aciorX //'tv/s
'•'•In the hcalthy control group putalive determinants of FX levels
jnvestigated. The mcan 1·Χ level in ihe 473 conirols was 103.5 U/dl
, 49 to 16.3). Bccausc I :X Icvcls an- known lo be influenced by
;-OraI conlraceptivc usc (34). mean FX levels \scre calculated for sub-
i-groups according to oral comraceptive us-c. In mcn, the raean FX level
[' was 103.6 U/dl (W.'c Cl: 102-106. n = 2()h. Sirnilar FX levels were
|j'detected in postmcnopausal woincn (mcan 104.4 U/dl, 95% CI: 101 to
:108, n =' 90). Prcmenopausal womcn who were not using oral contra-
'ittptives (-OC) at venepunclure tiine had a mean l-'X level of 95.1 U/dl
' 5% Cl: 92-98. n = 99). Highest ΓΧ Icvcls weie found in preme-
x'nopausal women who were usina oral contraceptives (+OC) (mean
vj 18.0 U/dl: 95% Cl : 1 1 3- 1 23. n = 54). No relai ionship between age and
(levels was found.
KtorX Levels and Ki.\k of VCIIOIH Thronibosü
he 90th perccntile of FX levels in conlroU was 126 U/dl. Sixteen
t of thc paticnls and, by dellnilion. l ()' Ί of the controls had a FX
dabove this cut-off value, indicatmg a 1.6-l'old increased risk of
; thrombosis for subjccls with a FX level > 126 U/dl compared
»subjecis wilh levels below this cul-off (cnide OR = 1.6, 95% CI:
IA, Table 2). Adjustmcnl for age and scx tlid not change this OR.
itment for age, sex and oral eontracepii\e use resulted in an OR of
! (95% Cl: 1.2-2.7). Addilional correction for other vitamin K-de-
nt coagulation proteins (Fl!. FVII and 1-IX. all dichotomized at
^the 9()th pereenlile) reduced the OR 10 1.2 (95',; CI: 0.8-1.9). In this
):'v.Same logistic model (sex, age, oral contraceptive use and vitamin K-de-
pendent proteins ΙΊΙ, FVII, FIX and FX. all dichotomized at the 90th
.̂..percentile) the adjustcd ORs for the other vitamin K-dependent proteins
were 1.4 (95% CI: 0.9-2.2) for high FII levels (above 90th percentile,
> 123 U/dl), 1.3 (95% CI: 0.8-2.0) for high FVII levels (above 90th
percentile, > 139 U/dl) and 2.3 (95% CI: 1.5-3.5) for high FIX levels
(above 90th percentile, > 130 U/dl). Without adjustment for other vita-
min K-dependent proteins these ORs were 1.8 (95% CI: 1.2-2.7) for
high HI levels, 1.6(95%CI: 1.1-2.5) for high FVII levels and 2.7 (95%
Q: l .8-4.1) for high FIX levels.
Comparing FX levels of patients and controls in different subgroups
according to oral contraceptive use, äs depicted in Fig. l, showed a
similar distribution of FX levels in patients and controls for men, post-
menopausal women and premenopausal women (+OC). However, for
premenopausal women (-OC) the distribution of FX levels in patients
and controls was different. Premenopausal patients (-OC) tended to
have higher FX levels than premenopausal controls (-OC), who had the
lowest FX levels. For that reason the thrombosis risk associated with a
FX level above the 90th percentile was highest (crude OR = 4.3,95%
CI: 1.5-12, Table 2) in this subgroup. After correction for age and vita-
min K-dependent proteins (FII, FVII, FIX) this OR reduced to 1.6 (95%
CI: 0.4-5.6). for men the crude OR was 1.9 (95% CI: 1.0-3.8) and after
correction for age and the vitamin K-dependent proteins 1.4 (95% CI:
0.7-2.9). Lowest risks were found in postmenopausal women (crude
OR = 1.6, 95% CI: 0.5-4.8) and in-premenopausal women (+OC)
(crude OR = 1.1,95% CI: 0.4-2.8).
Table 3 shows the ORs after stratification of the FX levels into four
groups. Subjects with FX levels above 140 U/dl had a 2.1-fold in-
creased risk compared with those with a FX level below 100 U/dl.
After adjustment for age, sex and oral contraceptive use this OR
became 2.7 (95% CI: 1.3-5.6). Additional correction for vitamin K-de-
pendent proteins (FII, FVII, FIX) resulted in an OR of l .6 (95% CI: 0.7-
3.5).
The -222 C/T, -220 C/A and TTGTGA Insertion Promoter
Polymorphisms
Exon l to 8 and their flanking regions and the first 506 nucleotides
of the 5'-flanking region of the FX gene [numbering according to Miao
et al. (30)] were sequenced in a previously described panel of 28 pro-
bands of thrombophilic families and 5 healthy controls (10), using pri-
mer sets derived from the FX gene sequence (35-37). Three variations
were detected: the -222 C/T Variation, the -220 C/A Variation and a














































1.9 1.0 - 3.8
4.3 1.5 - 12
1.1 0.4-2.8
1.6 0.5-4.8
* Oral contraceptive use for premenopausal patients both at thrombosis date and at
venepuncture (28)
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t OR adjusted for age, sex, oral contraceptive use and vitamin K-dependent coagulation
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Ttible 4 h'acu»r X promcrterpolymixpfcie»
* -220 C/A and TTGTGA insertion between -343A and -342G were only detcrmined in
homozygous -222 CC and TT, camers
tn=230
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3A iriscrtion belwecn -343Λ and -3420. These three variations
ifiSlso be'detcclecl by comparing the 1;X promoter sequences which
IpSeteported by Miao et al. (30) and Huang et id. (32). In agroup of 97
C volunteers (48 mcn and 49 wornen of whom 19 were using oral
eptives at venepunciure lirne) we looked at these three porymor-
> and their rclationship wi lh FX levels. .-\nalyses suggested that
i of tlie [T'IVCC/- -| (-222C/T. -22()C/.\ and no insertion fol-
;-343A, respcclively) genolypc had higher FX levels (mean 109.4,
i Cl: 102-116, n = 22") than carriers of the [CC/AA/+ +] genotype
. 94.4, 95% G: 87-102, n - 14). also after exclusion of oral
rädtraceptive users. Because of t he observed difference in FX levels
i the iwo extreme haploiypes in this sraall study we chose the
owing approach for screening of the polyinorphisms in LETS: first,
cts wcre screcncd for Ihe -222 C/T polymorphism in the FX
Promoter region (Tablc 4). Subscquunlly, all homözygous -222 CC and
*iFr'cairiers wcre screencd for the -220 (7A and TTGTGA insertion
-343A and -342G. The three polyinorphisms showed a high
£;,(fcgreeof linkage disequilibrium: a -220 Λ allele was always accompa-
?sJÜ6dby the insertion and a C allele al -222 Λ. The relationship between
1 -̂222 C/T polymorphism and I-'X levels was assessed in the healthy
*''" 1 subjects/Mean FX levels were 102.9 U/dl (95% CI: 100-106,
144) for hormvygous -222 CC carriers, 104.2 U/dl (95% CI:
|ίβΜ06, n = 230) for helero/ygous -222 CT carriers and 102.6 U/dl
|ί"Κ% CI: 99.6-106, n = 99) Ibr hoino/.ygous -222 TT carriers. Com-
l of the FX levels of the iwo extreme gcnotypes [CC/AA/+ +] and
Ί- -] did also not reveal any difference in the total cohtrol group
jjjrin the different subgroiips (mcn. poslmcnopausal women, and pre-
***' sal women-OCor'+OC). \
^40 C/T Promoter Polymorphism
y, an additiönal polymorphism (-40 C/T) in the promoter
f the FX üftie was ic|V>rtrtl ΟΠ. The T allele was reported to
; witli an incivased risk of coronary artery disease. All
isubjccts were scrcened for this polymorphism. Two out of 471
> were homo/.ygous for the T allele and 36 were heterozygous
feie frequcncy 4.2%). Forty-l'ivc of 472 controls were heterozygous
Ü ftrthe'T allele and none of the controls was homözygous for the T al-
i'fcle (allele frequency 4.8%). The odds ratio (OR) for subjects carrying
£6e T allele (in hctero/ygous or homo/.ygous form) was 0.8 (95% CI:
HJÜ-1.3). In healthy controls we invesligated the relationship between
lSfe-40 C/T polymorphism and FX levels. Mean FX levels were 103.6
f\M (95% CI: 102-105) for homo/ygous wildtype -40 C camers and
'|||te;3.U/dl (95% CI: 97.4-108) for'the heierozygous -40 CT camers.
zing mean FX levels for the two genotypes in the various
: (men, poslmcnopausal womcn and premenopausal women
|-flCor +OC) also did nol reveal any difference in FX level. The 2 post-
female patients who were carrying the 40 T allele in
ygous form had FX levels of 84 and 92 U/dl.
|ΐ 'Our study shows that arnong healthy conirols FX plasma levels are
r in premenopausal women who are not using oral contraceptives
l than in mcn and poslmcnopausal women. These results corre-
:-.,̂ ond with previous Undings of Henkens et al. (38). Highest FX levels
rlwifEfound in premenopausal women who were using oral contracep-
tiVes (+OC). An increasc of I-'X levels and oiher procoagulant proteins
· during oral contraccplive iw has been reporied before (34,39). We did
P.find an effect of age on FX levels.
The crude OR, calculated äs an estimation of the relative risk of
venous thrombosis, for subjects with high FX levels (above the 90th
percentile, > 126 U/dl) compared with subjects with low FX levels
(< 126) was 1.6 with the highest risk found in the subgroup of preme-
nopausal women (-OC) (crude OR = 4.3). This tendency of higher FX
levels in premenopausal patients (-OC, group 3) than in premenopausal
controls (group 4) is visualized in Fig. 1. Comparing healthy preme-
nopausal control women (groups 4 and 6) shows that FX levels rise
strongly during oral contraceptive use, äs was already described above.
On the other band, premenopausal patients (+OC, group 5) have only
slightly higher FX levels compared to premenopausal patients (-OC,
group 3). So, it seems that in women who already have high FX levels,
oral contraceptive use does not increase these levels further. Preme-
nopausal patients and controls who are using oral contraceptives
(groups 5 and 6) have therefore similar FX levels and no thrombosis
risk associated with increased FX levels is found in this particular
subgroup. A similar observation was made for factor IX (12). High FIX
levels were shown to be a common risk factor for venous thrombosis
with the highegt risk found in premenopausal women (-OC). However,
high FIX levels remained a risk factor after adjustment for possible
confounders (oral contraceptive use and vitamin K-dependent clotting
proteins FII, FVII and FX), whereas the thrombosis risk associated with
higbFX levels was largely reduced after correction. When the vitamin
K-dependent proteins FII, FVII, FIX and FX are all included in one
model only high FIX levels remain a risk factor for venous thrombosis.
This indicates that the observed increased risk associated with high FX
levels may be explained by high levels of FIX, which has previously
been reported äs risk factor for venous thrombosis (12). It is interesting
that elevated levels of FIX (12) and of its cofactor FVIII (11) were both
found to increase the thrombosis risk, whereas elevated levels of FX
and its cofactor FV (40) were both found not to be risk factors.
Genetic variations that modulate the transcription of coagulation
factor genes and thereby influence protein levels, have been reported in
a number of studies. For example, a polymorphic Variation in the
promoter region of the protein C gene has been shown to influence
transcriptional efficiency in vitro and to be correlated with plasma
protein C levels (24, 41). Polyinorphisms in the promoter region of the
genes for PAI-1 (25), ß-fibrinogen (23) and FVII (22) and a Variation in
the 3'-untranslated region of the prothrombin gene (10) have also been
reported to be correlated with protein levels. We investigated four
polymorphisms in the promoter region of the FX gene. For one of
these polymorphisms (-40 C/T) it was recently reported that the T al-
lele was associated with an increased risk of coronary artery disease
(T allele frequency 4.4% in patients and 1.2% in controls) (31). The
polymorphic site at position -40 is located nearby a previously de-
scribed binding site for transcription factors HNF-4 and Sp-1 (nt -73 to
-44) in the FX promoter region (21, 30). A nucleotide Variation on
adjacent position -40 may interfere with binding of a transcription
factor and thereby influence gene expression. However, in LETS we
found no association between this polymorphism and FX levels and
also no association of the -40 T allele with thrombosis risk.
In addition to the -40 C/T polymorphism we screened for three other
promoter polymorphisrns (-222 C/T, -220 C/A and a TTGTGA inser-
tion between -343A and -342G). A small pilot study suggested that
camers of two extreme genotypes [TT/CC/- -] and [CC/AA/+ +] had
different mean FX levels. Therefore we first screened all subjects for
the -222 C/T polymorphism and next screened all homözygous
-220 CC and TT carriers for the other two variations assuming that
homözygous carriers of the -220 polymorphism would have the most
extreme effects. However, in this present large study the previously
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observed association between the different genotypes and FX levels
could not be confirmed.
In conclusion, we showed (hat high FX levels are not a risk factor for
venous thrombosis when other vitarain K-dependent clotting factors are
taken into account. Furthermore, no association between polymor-
phisms in the promoter of the FX gene and FX levels was observed.
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The thyroid and environment has been selected äs the topic for the first Symposium m the
new millenmum for the wellknown biennal International Merck Symposia on thyroid dis
eases, takmg place in Budapest m June 2000 This book contams 25 ma|or contnbuhons,
4 short Communications and 55 posterabstracts on the latest scientific research on a wide
ränge of environmental factors affectmg the thyroid
Session l "Environment, goiter and hypothyroidism" deals with the mfluence of environ
mental factors on mduction and climcal course of goiter and hypothyroidism
Session 2 "Environment and autoimmune thyroid disease" focusses on autoimmune thy
roid diseases triggered by smoking, stress, excessive lodme-mtake, mfections and other envi
ronmental factors
Session 3 "Environment and thyroid cancer" discusses the connection between lodme-
mtake radiation and oncogenes and the mcidence and histological gradmg of thyroid can
cer
Session 4 "Environment and non-autoimmune hyperthyroidism' mvestigates the epide-
miology, pathogenesis and especially the transition from genolype to phenotype of this
disease
The last Session "Environment an non autoimmune thyroiditis" delmeates the subacute
thyroiditis de Quervam, post radiation thyroiditis and bactenal mfections of the thyroid
This Symposium documentahon offers a broad and up-to-date survey of the manifold mterac
tions between environmental factors and thyroid diseases
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